Amgen (AMGN), Massachusetts General Hospital (MGH) and the Broad Institute have entered inot a strategic collaboration to jointly discover and validate new therapeutic targets and develop novel therapies for inflammatory bowel disease (IBD).
The collaboration will leverage the shared expertise of its participating scientists and partner institutions to discover and develop novel therapies for IBD.
It brings together scientists with expertise in clinical medicine, IBD biology, human genetics, genomic technology as well as drug discovery to work together to help create a new world of therapeutic options for IBD patients.
Under the MGH-Broad-Amgen collaboration, patient DNA samples will be collected and analyzed to identify and further validate genetic targets, biological assays to probe gene function, and subsequent drug discovery and development activities.
A new joint steering committee will be formed under the collaboration in order to select and guide projects.